Centella Asiatica Extract
drug drugOn this page
Also known as Asiatic pennywort leafAsiatic pennywort triterpenoidsAsiatic pennywort wholeBacopa wholeBrahmi wholeCentella asiaticaCentella asiatica leafCoastal water-hyssop wholeComplehealFespixonGotu kolaGotu kola leafGotu kola wholeHerba centellaeHydrocotyleHydrocotyle asiaticaHydrocotyle asiatica leafHydrocotyle erecta leafIndian pennywort whole
Summary
Centella Asiatica Extract (CHEMBL5095437) is a phase-3 clinical-stage unknown; indicated across 5 conditions including diabetic neuropathy and injury.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 5 conditions
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5095437 |
| Name | Centella Asiatica Extract |
| Type | Unknown |
| Max phase | 3 |
Also known as: Asiatic pennywort leaf, Asiatic pennywort triterpenoids, Asiatic pennywort whole, Bacopa whole, Brahmi whole, Centella asiatica, Centella asiatica extract, Centella asiatica leaf, Coastal water-hyssop whole, Compleheal, Fespixon, Gotu kola
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| diabetic neuropathy | 2 | MONDO:0006626 | EFO:1000783 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 6 |
| Not specified | 2 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03815305 | PHASE4 | UNKNOWN | Effect of Centella Asiatica on Xerotic Skin in Diabetes Mellitus Type 2 |
| NCT04669119 | PHASE4 | UNKNOWN | Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy. |
| NCT05271708 | PHASE4 | COMPLETED | Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery |
| NCT05317442 | PHASE4 | TERMINATED | Open-label Study to Evaluate the Efficacy and Safety of Fespixon Cream for the Treatment of Pressure Injury in Sacrum and Greater Trochanter Wound |
| NCT05338463 | PHASE4 | COMPLETED | Fespixon Cream for the Treatment of Chronic Diabetic Foot Ulcers (TEXAS 1A, 2A) in Dialysis Patients |
| NCT05438251 | PHASE4 | TERMINATED | Exploring the Effect of Fespixon Cream for the Treatment of Diabetic Foot Ulcers (TEXAS 3A, 3B) |
| NCT02616042 | PHASE3 | COMPLETED | The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis |
| NCT04886882 | EARLY_PHASE1 | UNKNOWN | Topical Agents Containing Magnesium Sulfate & Wound Healing in the Rat Model |
| NCT06472791 | Not specified | NOT_YET_RECRUITING | Centella Asiatica in Older Adults |
| NCT03270436 | Not specified | COMPLETED | Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: diabetic neuropathy